Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of Ozempic. This new drug stimula

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, rates of bariatric surgeries dropped by 25%, while prescriptions for weight-loss drugs more than doubled.

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent of their body weight in a year), it also appears to have many benefits beyond just weight loss.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a higher risk of inhaling gastric contents into their lungs while under

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and osteoarthritis.

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).

From constipation to muscle loss, the side effects of some weight loss and diabetes medications can be daunting to patients. CNN’s Dr. Sanjay Gupta looks at why these effects occur, and gives some tips on how to keep them in check.

"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports of the research.